Literature DB >> 2393274

Pharmacokinetic analysis of cloxacillin loss in children undergoing major surgery with massive bleeding.

M Levy1, P Egersegi, A Strong, A Tessoro, M Spino, R Bannatyne, D Fear, J C Posnick, G Koren.   

Abstract

To determine the magnitude of cloxacillin loss during surgical procedures involving significant blood loss and high fluid replacement, we compared the pharmacokinetics of cloxacillin in children during craniomaxillofacial surgery with the disposition of the drug in healthy young adult volunteers with intact circulation. Blood loss during craniofacial operations may exceed blood volume, in some cases by as much as three times. Hemodynamic replacement with electrolyte solutions and blood products, which do not contain the drug, further dilute cloxacillin concentrations. In the patients that we studied, mean drug loss was estimated at 71%. Cloxacillin concentrations in serum fell below the lower range of the MIC for Staphylococcus aureus during significant portions of the surgical procedures. Thus, the traditional dosing of cloxacillin during prolonged operations with massive blood loss is inadequate. A more frequent dosing interval or priming of all replacement fluids with the drug may be required to maintain therapeutic levels. Our findings suggest that massive blood loss is likely to have a dramatic effect on the level of any drug with a small distribution volume. If such a drug is essential to the patient's well-being (e.g., antibiotics, antiarrhythmics, and anticonvulsants), it must be replaced promptly.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393274      PMCID: PMC171775          DOI: 10.1128/AAC.34.6.1150

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  CLOXACILLIN: ACTIVITY IN VITRO, AND ABSORPTION AND URINARY EXCRETION IN NORMAL YOUNG MEN.

Authors:  J W KISLAK; T C EICKHOFF; M FINLAND
Journal:  Am J Med Sci       Date:  1965-06       Impact factor: 2.378

2.  Postoperative wound infection: a computer analysis.

Authors:  A E Davidson; C Clark; G Smith
Journal:  Br J Surg       Date:  1971-05       Impact factor: 6.939

3.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

Review 4.  Pharmacokinetics of the penicillins in man.

Authors:  M Barza; L Weinstein
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 5.  Antibiotic prophylaxis in surgical procedures. A critical analysis of the literature.

Authors:  B J Guglielmo; D C Hohn; P J Koo; T K Hunt; R L Sweet; J E Conte
Journal:  Arch Surg       Date:  1983-08

Review 6.  Semisynthetic penicillins.

Authors:  G N Rolinson; R Sutherland
Journal:  Adv Pharmacol Chemother       Date:  1973

7.  A rapid high performance liquid chromatographic procedure for the analysis of cloxacillin and/or nafcillin in serum.

Authors:  S J Soldin; A M Tesoro; S M MacLeod
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

8.  Effective and creative surveillance and reporting of surgical wound infections.

Authors:  A B Kaiser
Journal:  Infect Control       Date:  1982 Jan-Feb

9.  Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis.

Authors:  E H Nauta; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

10.  Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens.

Authors:  D A Goldmann; C C Hopkins; A W Karchmer; R M Abel; M T McEnany; C Akins; M J Buckley; R C Moellering
Journal:  J Thorac Cardiovasc Surg       Date:  1977-03       Impact factor: 5.209

View more
  1 in total

1.  Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplant patients.

Authors:  P M Arnow; K Furmaga; J P Flaherty; D George
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.